Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H19N5O6S2 |
Molecular Weight | 453.493 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SCC([C@@H]3CCCO3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C4=CSC(N)=N4)C(O)=O
InChI
InChIKey=ZJGQFXVQDVCVOK-QFKLAVHZSA-N
InChI=1S/C17H19N5O6S2/c1-27-21-10(8-6-30-17(18)19-8)13(23)20-11-14(24)22-12(16(25)26)7(5-29-15(11)22)9-3-2-4-28-9/h6,9,11,15H,2-5H2,1H3,(H2,18,19)(H,20,23)(H,25,26)/b21-10-/t9-,11+,15+/m0/s1
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.zora.uzh.ch/40272/4/Cefovecin.pdf | http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/veterinary/000098/WC500062064.pdf
Curator's Comment: description was created based on several sources, including:
http://www.zora.uzh.ch/40272/4/Cefovecin.pdf | http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/veterinary/000098/WC500062064.pdf
Cefovecin is a third generation cephalosporin with a broad-spectrum of activity against Gram-positive and Gram-negative bacteria. Cefovecin differs from other cephalosporins in that it is highly protein bound and has a long duration of activity. As with all cephalosporins, the bactericidal action of cefovecin results from the inhibition of bacterial cell wall synthesis through binding to the penicillin-binding proteins (PBPs). It is indicated for the treatment of skin infections secondary superficial pyoderma, abscesses and wounds. Some gastrointestinal adverse effects like vomiting, anorexia or diarrhea were observed.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16801403
Curator's Comment: # Pfizer, Inc.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Convenia Approved UseCONVENIA is indicated for the treatment of skin infections (secondary superficial pyoderma,
abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis and skin infections (wounds and abscesses) in cats, caused by susceptible strains of Pasteurella multocida. Launch Date2008 |
|||
Curative | Convenia Approved UseCONVENIA is indicated for the treatment of skin infections (secondary superficial pyoderma,
abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis and skin infections (wounds and abscesses) in cats, caused by susceptible strains of Pasteurella multocida. Launch Date2008 |
|||
Curative | Convenia Approved UseCONVENIA is indicated for the treatment of skin infections (secondary superficial pyoderma,
abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis and skin infections (wounds and abscesses) in cats, caused by susceptible strains of Pasteurella multocida. Launch Date2008 |
Sample Use Guides
A single injection of 8 mg/kg body weight. A second injection of 8 mg/kg may be administered if response
to therapy is not complete.
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C357
Created by
admin on Sat Dec 16 16:48:25 GMT 2023 , Edited by admin on Sat Dec 16 16:48:25 GMT 2023
|
||
|
CFR |
21 CFR 522.311
Created by
admin on Sat Dec 16 16:48:25 GMT 2023 , Edited by admin on Sat Dec 16 16:48:25 GMT 2023
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
CONVENIA (AUTHORISED)
Created by
admin on Sat Dec 16 16:48:25 GMT 2023 , Edited by admin on Sat Dec 16 16:48:25 GMT 2023
|
||
|
WHO-VATC |
QJ01DD91
Created by
admin on Sat Dec 16 16:48:25 GMT 2023 , Edited by admin on Sat Dec 16 16:48:25 GMT 2023
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
CONVENIA (AUTHORISED)
Created by
admin on Sat Dec 16 16:48:25 GMT 2023 , Edited by admin on Sat Dec 16 16:48:25 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
0D1OL46ZIE
Created by
admin on Sat Dec 16 16:48:25 GMT 2023 , Edited by admin on Sat Dec 16 16:48:25 GMT 2023
|
PRIMARY | |||
|
234096-34-5
Created by
admin on Sat Dec 16 16:48:25 GMT 2023 , Edited by admin on Sat Dec 16 16:48:25 GMT 2023
|
PRIMARY | |||
|
C76035
Created by
admin on Sat Dec 16 16:48:25 GMT 2023 , Edited by admin on Sat Dec 16 16:48:25 GMT 2023
|
PRIMARY | |||
|
DTXSID00177963
Created by
admin on Sat Dec 16 16:48:25 GMT 2023 , Edited by admin on Sat Dec 16 16:48:25 GMT 2023
|
PRIMARY | |||
|
6336480
Created by
admin on Sat Dec 16 16:48:25 GMT 2023 , Edited by admin on Sat Dec 16 16:48:25 GMT 2023
|
PRIMARY | |||
|
CHEMBL2110625
Created by
admin on Sat Dec 16 16:48:25 GMT 2023 , Edited by admin on Sat Dec 16 16:48:25 GMT 2023
|
PRIMARY | |||
|
300000023753
Created by
admin on Sat Dec 16 16:48:25 GMT 2023 , Edited by admin on Sat Dec 16 16:48:25 GMT 2023
|
PRIMARY | |||
|
0D1OL46ZIE
Created by
admin on Sat Dec 16 16:48:25 GMT 2023 , Edited by admin on Sat Dec 16 16:48:25 GMT 2023
|
PRIMARY | |||
|
8225
Created by
admin on Sat Dec 16 16:48:25 GMT 2023 , Edited by admin on Sat Dec 16 16:48:25 GMT 2023
|
PRIMARY | |||
|
1591901
Created by
admin on Sat Dec 16 16:48:25 GMT 2023 , Edited by admin on Sat Dec 16 16:48:25 GMT 2023
|
PRIMARY | RxNorm | ||
|
C516253
Created by
admin on Sat Dec 16 16:48:25 GMT 2023 , Edited by admin on Sat Dec 16 16:48:25 GMT 2023
|
PRIMARY | |||
|
Cefovecin
Created by
admin on Sat Dec 16 16:48:25 GMT 2023 , Edited by admin on Sat Dec 16 16:48:25 GMT 2023
|
PRIMARY | |||
|
m3207
Created by
admin on Sat Dec 16 16:48:25 GMT 2023 , Edited by admin on Sat Dec 16 16:48:25 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)